• Something wrong with this record ?

Gene expression changes in human prostate carcinoma cells exposed to genotoxic and nongenotoxic aryl hydrocarbon receptor ligands

E. Hrubá, J. Vondráček, H. Líbalová, J. Topinka, V. Bryja, K. Souček, M. Machala,

. 2011 ; 206 (2) : 178-88. [pub] 20110723

Language English Country Netherlands

Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

Carcinogenic polycyclic aromatic hydrocarbons (PAHs) are known as efficient mutagens and ligands of the aryl hydrocarbon receptor (AhR), which has been suggested to play an important role in prostate carcinogenesis. In order to evaluate the complex relationship between the genotoxicity and the AhR-mediated activity of PAHs in prostate cells, we selected benzo[a]pyrene (BaP) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), as model genotoxic and nongenotoxic AhR ligands, respectively, to explore global changes in gene expression in LNCaP cells by microarray analysis. We identified 112 genes that were differentially expressed in cells treated for 24h with BaP, TCDD or both compounds. Our data indicated that the impacts of BaP and TCDD on transcriptome of LNCaP cells significantly overlap, since over 64% of significantly up-regulated genes and 47% of down-regulated genes were similarly affected by both AhR ligands. This suggested that the activation of AhR played a prominent role in the nongenotoxic effects of BaP in the prostate carcinoma cell model LNCaP. Both AhR ligands suppressed expression of genes associated with cell cycle progression, DNA replication, spindle assembly checkpoint or DNA repair, which probably occurred secondary to inhibition of cell cycle progression. In contrast, we identified Wnt5a, an important regulator of prostate cancer progression, to be induced as early as 6h after exposure to both AhR ligands. The AhR ligand-induced Wnt5a upregulation, together with other observed alterations of gene expression, may further contribute to enhanced cell plasticity of prostate carcinoma cells.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12028141
003      
CZ-PrNML
005      
20121210100911.0
007      
ta
008      
120817e20110723ne f 000 0#eng||
009      
AR
024    7_
$a 10.1016/j.toxlet.2011.07.011 $2 doi
035    __
$a (PubMed)21802500
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Hrubá, Eva $u Department of Toxicology, Pharmacology and Immunotherapy, Veterinary Research Institute, Hudcova 70, Brno, Czech Republic.
245    10
$a Gene expression changes in human prostate carcinoma cells exposed to genotoxic and nongenotoxic aryl hydrocarbon receptor ligands / $c E. Hrubá, J. Vondráček, H. Líbalová, J. Topinka, V. Bryja, K. Souček, M. Machala,
520    9_
$a Carcinogenic polycyclic aromatic hydrocarbons (PAHs) are known as efficient mutagens and ligands of the aryl hydrocarbon receptor (AhR), which has been suggested to play an important role in prostate carcinogenesis. In order to evaluate the complex relationship between the genotoxicity and the AhR-mediated activity of PAHs in prostate cells, we selected benzo[a]pyrene (BaP) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), as model genotoxic and nongenotoxic AhR ligands, respectively, to explore global changes in gene expression in LNCaP cells by microarray analysis. We identified 112 genes that were differentially expressed in cells treated for 24h with BaP, TCDD or both compounds. Our data indicated that the impacts of BaP and TCDD on transcriptome of LNCaP cells significantly overlap, since over 64% of significantly up-regulated genes and 47% of down-regulated genes were similarly affected by both AhR ligands. This suggested that the activation of AhR played a prominent role in the nongenotoxic effects of BaP in the prostate carcinoma cell model LNCaP. Both AhR ligands suppressed expression of genes associated with cell cycle progression, DNA replication, spindle assembly checkpoint or DNA repair, which probably occurred secondary to inhibition of cell cycle progression. In contrast, we identified Wnt5a, an important regulator of prostate cancer progression, to be induced as early as 6h after exposure to both AhR ligands. The AhR ligand-induced Wnt5a upregulation, together with other observed alterations of gene expression, may further contribute to enhanced cell plasticity of prostate carcinoma cells.
650    _2
$a benzopyren $x toxicita $7 D001564
650    _2
$a karcinogeny životního prostředí $x toxicita $7 D002274
650    _2
$a karcinom $x metabolismus $7 D002277
650    _2
$a buněčný cyklus $x účinky léků $7 D002453
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a oprava DNA $x účinky léků $7 D004260
650    _2
$a replikace DNA $x účinky léků $7 D004261
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a ligandy $7 D008024
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a aparát dělícího vřeténka $x účinky léků $7 D008941
650    _2
$a mutageny $x toxicita $7 D009153
650    _2
$a sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů $7 D020411
650    _2
$a nádory prostaty $x metabolismus $7 D011471
650    _2
$a protoonkogenní proteiny $x genetika $x metabolismus $7 D011518
650    _2
$a receptory aromatických uhlovodíků $x agonisté $7 D018336
650    _2
$a polychlorované dibenzodioxiny $x toxicita $7 D000072317
650    _2
$a časové faktory $7 D013997
650    _2
$a proteiny Wnt $x genetika $x metabolismus $7 D051153
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vondráček, Jan
700    1_
$a Líbalová, Helena
700    1_
$a Topinka, Jan
700    1_
$a Bryja, Vítězslav
700    1_
$a Souček, Karel
700    1_
$a Machala, Miroslav
773    0_
$w MED00004537 $t Toxicology letters $x 1879-3169 $g Roč. 206, č. 2 (20110723), s. 178-88
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21802500 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120817 $b ABA008
991    __
$a 20121210100948 $b ABA008
999    __
$a ok $b bmc $g 950183 $s 785487
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 206 $c 2 $d 178-88 $e 20110723 $i 1879-3169 $m Toxicology letters $n Toxicol Lett $x MED00004537
LZP    __
$a Pubmed-20120817/11/04

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...